Plain-English translation of NCT06279026 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new treatment called , which uses specially engineered immune cells to fight multiple myeloma—a type of blood cancer that has stopped responding to previous treatments. Researchers want to find the safest and most effective dose, and to see how well this medication works for patients who have tried at least three other treatment approaches without success.
Multiple myeloma that comes back or doesn't respond to standard treatments is very difficult to manage, and patients need new options. This trial exists to determine whether this new cell-based treatment could offer hope for people in this situation.
You likely qualify if…
You likely don't qualify if…
You would receive a single infusion of the UTAA17 treatment after some preparation. Over the following months, you would have regular blood draws and clinic visits at weeks 4, 2 months, 3 months, 6 months, and then every 3 months for up to 24 months after the infusion to check how your cancer is responding and monitor for any side effects.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
China